Document resource
Background and Importance Aflibercept is an anti-vascular endothelial growth factor drug that prevents damaged blood vessels from leaking fluid into the macula. This helps to treat or prevent age-related macular degeneration (ARMD)Aim and Objectives To evaluate the effectivity and durability of intravitreal aflibercept in treatment-naïve and those switched from ranibizumab.Material and Methods A retrospective observational study was conducted on ARMD patients treated with aflibercept treatment between April 2024 and April 2025, with at least a loading dose administered.Data collected included demographics and clinical information: treatment-naïve or prior switched from ranibizumab, number of previous intravitreal injections, baseline and final best-corrected visual acuity (BCVA) in logMAR scale, and the dosing interval (Q) in weeks before and after starting aflibercept therapy.The statistical analyses were performed using SPSS version 29.0Results 66 patients (60.6% female, mean age 79 ± 9.7 years) and 72 eyes were analysed: 22.2% naïve and 77.8% switched. The mean number of prior injections of ranibizumab was 10.6 ± 9.5.The mean overall BCVA was 0.508 ± 0.47 logMAR at baseline vs. 0.513 ± 0.52 logMAR at study end ([IC95% -0.005 (-0.11-0.10) p = 0.927)]. The difference between the final and baseline BCVA in naïve and switched patients was -0.184 ± 0.63 log MAR and in +0.059 ± 0.4 logMAR, respectively.In the switched group, the mean Q previous treatment with aflibercept was 6.01 ± 1.81 weeks (34% Q4W; 66% Q6–8W). At study end, the mean Q increased to 8.27 ± 2.77 weeks (8% Q4W; 64% Q6–8W; 28% >Q10W).In the naïve group, the mean Q was 7.31 ± 3.99 weeks: Q: 33% Q4W; 26% Q6–8W; 41% >Q10W.7 (9.7%) patients discontinued treatment.Conclusion and Relevance Retinal diseases are rapidly progressing pathologies that require prompt initiation of treatment at diagnosis. While overall visual acuity remained stable, treatment-naïve patients experienced modest improvement in visual acuity. Aflibercept enabled extended injection intervals in both groups, particularly in naïve patients. Larger real-world studies with longer follow-up are warranted to confirm these findings and to optimise treatment strategies.Conflict of Interest No conflict of interest